Grasim Industries Reports No Deviation in Fund Utilisation

📊

submitted its Q3FY26 monitoring agency report for the ₹3,999.80 crore rights issue, with CARE Ratings Limited certifying that there has been no deviation or variation in the utilisation of proceeds, reflecting adherence to stated objectives.